《美股業績》Biogen(BIIB.US)阿茲海默症藥季度銷售遠遜預期
美國神經系統藥企渤健(Biogen)(BIIB.US)公佈去年第四季業績。季度純利3.68億美元,按年升3%。每股季度攤薄純利2.5美元。季度收入27.34億美元,按年跌15%。
公司阿茲海默症藥Aduhelm季度銷售100萬美元,遠低於市場預期的280萬美元。美國醫保計劃上月提出限制阿茲海默症藥物的覆蓋範圍,至限於參與已獲凌臨牀測試的病人。渤健的Aduhelm將受影響,最終決定將於4月作出。公司警告若該藥保險覆蓋較公司提出的爲小,公司將須在目前每年節省5億美元成本的計劃下進一步削減開支。
公司預期現財年經調整每股純利介乎14.25至16美元,低於市場預期的18.82美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.